Form D · Pharmaceuticals

Faraday Pharmaceuticals, Inc.

Seattle, WA · CIK 0001614107

Offering snapshot reported Nov 7, 2022 · SEC filing

Reported sold
$52.8M
Offering amount: $103M
Investors reported
3
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 24, 2022
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 7, 2022Initial$52,826,124No comparison3SEC filing
Sep 12, 2019Initial$25,065,950No comparison8SEC filing
Mar 19, 2019Initial$5,000,000No comparison7SEC filing
Feb 21, 2017Amendment$32,606,754$28,949,480vs Jul 23, 201411SEC filing
Jul 23, 2014Initial$3,657,274No comparison4SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-464006

Source: Form D, filed Nov 7, 2022. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Brian Blackman Executive
Steven Gillis Director
Lawrence Gozlan Director
Stephen Hill Director, Executive
Paulina Hill Director
Ronald Kierpa Executive
Thomas King Director
Terrance Mc Guire Director
Robert Nelsen Director
Patrick Rock Executive
Mark Roth Director, Promoter
Simon Tulloch Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
1616 Eastlake Avenue E. Suite 560
Seattle, WA, 98102